Navigation Links
Gene Transfer Using Mutant Form of Good Cholesterol Cuts Vascular Plaque and Inflammation

Transfer of a gene that produces a mutant form of good cholesterol provides significantly better anti-plaque and anti-inflammation benefits than therapy// using the “normal” HDL gene, according to a mouse study conducted by cardiology researchers at Cedars-Sinai Medical Center and reported in the Oct. 3 issue of the Journal of the American College of Cardiology.

Apolipoprotein A-I is a naturally occurring component of normal HDL (high-density lipoprotein), the “good” cholesterol that circulates in the blood stream. Apolipoprotein A-I Milano is a mutant form, which was originally found in a small number of individuals in Italy who appear to be protected from cholesterol-related heart disease. Researchers are studying the possibility of treating vascular inflammation and plaque buildup through the transfer of protective genes.

“There has been uncertainty and controversy about whether apo A-I Milano is a better form of HDL than the “wild type” (regular) apo A-I in terms of protective effect against atherosclerosis and vascular inflammation, which are tied together,” said Prediman K. Shah, M.D., director of the Division of Cardiology and the Atherosclerosis Research Center at Cedars-Sinai.

“We used a unique approach to do a head-to-head comparison, which allowed us to conclusively ascertain the differences between the two genes. Our study demonstrated that A-I Milano gene transfer is much more effective in reducing plaque and vascular inflammation than the normal (wild type) form of apo A-I,” said Shah, the article’s senior author.

Compared to control, wild type apo A-I gene transfer led to about a 25 percent decrease in the amount of plaque buildup in the animals’ aortas and other vessels. Apo A-I Milano gene transfer resulted in a 65 percent reduction. The amount of gene product (protein) produced by each gene was identical, measured in the blood and in the plaque.

The experiments were conducted in female mice bred to lack the apo A-I gene and the apo E gene. Without these genes, they develop very high cholesterol levels and arterial plaque and are incapable of producing their own apo A-I.

“Any apo A-I that these mice have will come from our gene transfer, making the experimental design very clean,” Shah noted.

The genes were transferred to the female mice during a bone marrow transplant from male mice. Because male DNA carries a y chromosome and female DNA does not, the gender mismatch enabled the researchers to precisely track the donor bone marrow.

To deliver the gene to the arterial wall, the researchers used a “signal molecule” when they put the genes into the bone marrow. The signal molecule selectively goes into immune system cells called macrophages, which go into the arterial wall.

“We examined the ability of both the wild type and the apo A-I Milano gene to move cholesterol out of the macrophages, a process called cholesterol efflux. This is one of the mechanisms by which HDL and apo A-I work to reduce plaque: They facilitate the removal of cholesterol from the macrophages in the plaque and deliver it to the liver for elimination,” Shah said. “We used three methods in our experiment and all three methods demonstrated that macrophages containing the apo A-I Milano gene were more effective in effluxing cholesterol out of them, compared to those carrying the wild type apo A-I gene. Therefore, we concluded, the greater beneficial effect of A-I Milano gene transfer is most likely related to a greater efficiency of A-I Milano in promoting the removal of cholesterol from the macrophages.”

Shah, who holds the Shapell and Webb Family Endowed Chair in Cardiology at Cedars-Sinai, has been studying apo A-I Milano in its various forms for about 13 years. He and his colleagues developed a synthetic version of the protein and conducted animal studies at Cedars-Sinai that led to human trials at the Cleveland Clinic in which intravenous injections were found to shrink plaque in human coronary arteries.

Souce-Newswise
SRM
'"/>




Related medicine news :

1. Free Tissue Transfer Effective in Treating Massive Skin Cancers
2. Tissue Transfer for Skin Cancer
3. Tissue Transfer For Treatment Of Massive Skin Cancers
4. Transfer Of Rabies Virus Possible From Organ Donor To Recipient
5. Gene-Nanoparticle Gene Transfer Is Better Than Viral Vector Transfer System
6. Decreasing Multiple Births By Single Embryo Transfers
7. Therapeutic Genes Transferred By Viral Vector Through T Cell Masking
8. Biologicals Transfer Proposal between US and Indian Biotechnology
9. Punjabis Transfer Taste From Chicken To Prawns
10. Transplantation Results in CJD Transfer
11. Transfer of NHS hospital care into the community may not save costs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... Linda, Ca (PRWEB) , ... June 20, 2017 ... ... of alternative polyA sites. To understand their regulatory principles, the research team developed ... mRNA-Seq, iCLIP and RNA motif analyses. This reveals at nucleotide resolution the ‘RNA ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... , ... June 20, 2017 , ... The law firm ... on his installation as the president of the DuPage County Bar Association’s Board of ... Installation Dinner June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
Breaking Medicine Technology: